Companies · Other Health Care

ArcherDX, Inc.

BOULDER · Other Health Care

Diligence memoA one-page analyst read on ArcherDX, Inc. — recommendation, valuation, rhythm, risks.
$115.1M
Total raised · real
6
Rounds
1.2×
Latest step-up
Top 4%
Sector rank · raised
Series C
Latest stage · inferred · Mon Apr 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

ArcherDX, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.03× the median modeled value of Series C Other Health Care companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

ArcherDX, Inc. is one of 5377 Other Health Care companies tracked from BOULDER. By capital raised it ranks among the largest (ahead of 97% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020-04-27
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2018-03-05 Raised $38M (real) Modeled valuation $834M (est)$38M$834MSeries B2018Series B · 2019-05-10 Raised $15M (real) Modeled valuation $332M (est)$15M$332MSeries B2019Series C · 2019-12-11 Raised $55M (real) Modeled valuation $1.3B (est)$55M$1.3BSeries C2019Series C · 2019-12-17 Raised $4.6M (real) Modeled valuation $106M (est)$4.6M$106MSeries C2019Series C · 2020-02-26 Raised $1.3M (real) Modeled valuation $30M (est)$1.3M$30MSeries C2020Series C · 2020-04-27 Raised $1.6M (real) Modeled valuation $36M (est)$1.6M$36MSeries C2020+$15M+$55M+$4.6M+$1.3M+$1.6MCumulative $115M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$37.6M · 2018
Series B extension$15.0M · 2019
Series C$55.0M · 2019
Series C extension$4.6M · 2019
Series C extension$1.3M · 2020
Series C extension$1.6M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$35.6M
Base estimate est.
$5.7M
Conservative case
$93.9M
Upside case
$10.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series B · modeled $833.9M · 2018-03-052018Series B · modeled $332.3M · 2019-05-10Series C · modeled $1.3B · 2019-12-11Series C · modeled $105.9M · 2019-12-17Series C · modeled $29.7M · 2020-02-26Series C · modeled $35.6M · 2020-04-272020
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
6.2 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$53.6M/yr
Capital velocity
8.3 yr
On record since
2018
First round
6
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 47× above median
This company$115.1M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.6M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 1.6× above median
This company$35.6M
Sector median$22.1M

Raised more than 97% of sector peers (real $). Modeled value above 61% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #45 of 46.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Avail Medsystems, Inc. · Series C Raised $126.7M · modeled $2.2B (est)Whoop, Inc. · Series C Raised $180.4M · modeled $2.1B (est)HRGi Holdings, Inc. · Series C Raised $91.2M · modeled $2.1B (est)Ambulnz, Inc. · Series C Raised $90.0M · modeled $2.1B (est)MedAvail, Inc. · Series C Raised $97.0M · modeled $2.0B (est)SOC Telemed, Inc. · Series C Raised $103.0M · modeled $1.9B (est)Eargo, Inc. · Series C Raised $187.4M · modeled $1.9B (est)Truth Holdings, L.P. · Series C Raised $88.8M · modeled $1.6B (est)NeuroPace Inc · Series C Raised $208.6M · modeled $1.5B (est)DermTech, Inc. · Series C Raised $98.9M · modeled $1.5B (est)Mydna, Inc · Series C Raised $72.1M · modeled $1.4B (est)Ancora Heart, Inc. · Series C Raised $151.3M · modeled $1.4B (est)ArcherDX, Inc. (this company) Raised $115.1M · modeled $35.6M (est)ArcherDX, Inc.
CompanyStageRaised · realValue · estvs peer med.
Avail Medsystems, Inc.Series C$126.7M$2.2B1.87×
Whoop, Inc.Series C$180.4M$2.1B1.81×
HRGi Holdings, Inc.Series C$91.2M$2.1B1.81×
Ambulnz, Inc.Series C$90.0M$2.1B1.79×
MedAvail, Inc.Series C$97.0M$2.0B1.75×
SOC Telemed, Inc.Series C$103.0M$1.9B1.65×
Eargo, Inc.Series C$187.4M$1.9B1.61×
Truth Holdings, L.P.Series C$88.8M$1.6B1.43×
NeuroPace IncSeries C$208.6M$1.5B1.33×
DermTech, Inc.Series C$98.9M$1.5B1.29×
Mydna, IncSeries C$72.1M$1.4B1.26×
Ancora Heart, Inc.Series C$151.3M$1.4B1.24×
ArcherDX, Inc. this companySeries C$115.1M$35.6M0.03×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$37.6M2018-03-05$209.1M$833.9M90%
Series B$15.0M2019-05-10$83.3M$332.3M90%
Series C$55.0M2019-12-11$366.7M$1.3B90%
Series C$4.6M2019-12-17$30.9M$105.9M90%
Series C$1.3M2020-02-26$8.7M$29.7M90%
Series C$1.6M2020-04-27$10.4M$35.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$37.6M2018-03-05
    • First recorded raise — entered as Series B.
    • 31 investors on this round.
  2. Series B$15.0M2019-05-10
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 26 investors on this round.
  3. Series C$55.0M2019-12-11
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 3.7× larger than the prior — scaling up.
    • 37 investors on this round.
  4. Series C$4.6M2019-12-17
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 11.9× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  5. Series C$1.3M2020-02-26
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series C$1.6M2020-04-27
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~5mo cadence
$1.9M
Modeled next size est.range $1.6M$3.0M
1.2×
Last step-up
$53.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kyle Lefkoff8 other2018-03
Paul B. Manning5 other2020-04
Paul Manning5 other2018-03
Jason Myers3 other2018-03
Kyle A. Lefkoff1 other2020-04
Marvin Caruthers1 other2019-05
Marvin H Caruthers1 other2020-04
Steven J. Kafka1 other2020-04
Todd Druley1 other2019-12
Benjamin Carver2019-12
Britton A. Russell2020-04
Christian LaPointe2018-03
Jason C. Ryan2020-04
Jason W. Myers2020-04
Joshua C. Stahl2020-04
Joshua Stahl2019-12
Mark Massaro2019-12
Steven Kafka2019-05
Registry & provenance

ArcherDX, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1734551
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Miragen Therapeutics, Inc.BiotechnologySeries C$197.8M$3.3Bnetwork4 shared operators · same stage
Verrica Pharmaceuticals Inc.PharmaceuticalsSeries C$77.5M$269.0Mnetwork2 shared operators · same stage
BioHorizons, Inc.Other Health CareSeries C$64.1M$34.3Msame sector · same stage
TwinStrand Biosciences, Inc.Biotech / PharmaSeries C$85.0M$132.4Mnetwork1 shared operator · same stage
Sonendo, Inc.Other Health CareSeries C$241.5M$33.0Msame sector · same stage
Orthosensor, IncOther Health CareSeries B$112.8M$30.0Msame sector
Genapsys, Inc.BiotechnologySeries B$106.0M$871.9Mnetwork1 shared operator
Centinel Spine, LLCOther Health CareSeries D+$181.2M$34.3Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
FundRx, Inc.Other Health CareSeed$34.5M87%
assayaDx CorpOther Health CarePre-Seed$2.1M87%
Pymedix, Inc.Other Health CarePre-Seed$1.4M87%
Genomedx Inc.Other Health CareSeries B$176.3M87%
MetaModix, Inc.Other Health CareSeed$4.2M87%
NarrativeDx Inc.Other Health CareSeed$73.7M87%
PrismHealthDX, Inc.Other Health CareSeries A$113.0M86%
AmplifiDx, Inc.Other Health CarePre-Seed$6.1M86%
Frequently asked
How much funding has ArcherDX, Inc. raised?
ArcherDX, Inc. has raised approximately $115.1M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is ArcherDX, Inc.'s estimated valuation?
Provath's modeled valuation for ArcherDX, Inc. is approximately $35.6M (modeled range $5.7M–$93.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ArcherDX, Inc. at?
ArcherDX, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Mon Apr 27.
What does ArcherDX, Inc. do and where is it based?
ArcherDX, Inc. operates in the Other Health Care sector, based in BOULDER.
Explore related

See where ArcherDX, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ArcherDX, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.